BIOtechnology Applied to Renal TRansplantation With IMmunobiogram

Kidney Transplant Failure and Rejection Clinical Trial

— BIOTRAIM  

Official title:

Longitudinal Observational Study to Determine the Correlation Between Patient's Pharmacodynamic Response to Immunosuppressants Measured in Vitro With IMMUNOBIOGRAM and of Rejection in Graft Biopsies in Patients With Renal Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05816486
• Other study ID #: BH-IMBG-TR-2021
• Status: Recruiting
• Start date: December 1, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: February 2023
• Source: Biohope Scientific Solutions for Human Health, S.L.
• Contact: Isabel Portero
• Phone: +34 912 187 043
• Email: isabel.portero[@]biohope.eu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Immunobiogram (IMBG) is a novel in vitro diagnostic bioassay developed by Biohope Scientific Solutions for Human Health SL, that allows to measure the pharmacodynamic response to individual immunosuppressive drugs in patients with a renal transplantation. Pharmacodynamics can complement the already available pharmacokinetic information on immunosuppressants and enable a more individualized evaluation of the immunosuppressive therapy. The aim of this study is to evaluate the association between the pharmacodynamic response to individual immunosuppressants taken by the patient measured in vitro with IMBG and the existence of signs of graft rejection in biopsies (upon indication or protocol) performed in a sample of kidney transplant patients. The main hypothesis is that a lower sensitivity to the immunosuppressive drugs taken by the patient will be associated with a higher probability of rejection.

Description:

Immunobiogram (IMBG) is a novel bioassay that allows to measure in vitro the inhibitory effect of a battery of individual immunosuppressants on the patient's immune cells (immunologically stimulated PBMCs). Studies conducted in kidney transplant patients have shown that IMBG is a valid and accurate instrument, capable of determining each patient's pharmacodynamic response profile to individual immunosuppressive drugs. Health professionals who monitor kidney transplant patients currently have information only on immunosuppressant pharmacokinetics to adjust the regimen of the immunosuppressants they use to treat the patients to avoid graft rejection. The pharmacodynamic measurement of the in vitro effect of each immunosuppressant in the patient could complement the pharmacokinetic information and enable more personalized approaches. The main objective of this study is to evaluate the association between the pharmacodynamic response to individual immunosuppressants taken by the patient measured with IMBG and the existence of signs of graft rejection in biopsies (upon indication or protocol) performed in a sample of kidney transplant patients. A longitudinal follow-up cohort of patients will be recruited from prior to the transplant (at sites that regularly perform a protocol graft biopsy after a year) and a cross-sectional cohort of patients will also be included when an indication biopsy is performed during the first three years after kidney transplantation due to a suspicion of rejection at sites that do not routinely perform protocol biopsies. Given that one of the main challenges that clinicians face in the follow-up of patients is to reduce the risk of renal graft rejection, while minimizing the incidence of secondary effects related to immunosuppressive therapy, it is proposed as a secondary objective to evaluate in the longitudinal cohort the incidence of "therapeutical failure" due to graft failure or due to the appearance of serious adverse effects attributable to immunosuppression and analyze its relationship with the profile of sensitivity to immunosuppressants taken by the patient measured with IMBG. Finally, the changes over time presented by the IMBG in various determinations and the correlation between IMBG results and other lymphocyte activation parameters obtained by flow cytometry will be analyzed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: June 30, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Longitudinal cohort:

1. Patients > 18 years of age.

2. Candidate to receive a kidney transplant or re-transplant.

3. Patients in whom it is planned to routinely perform a protocol biopsy one year after the kidney transplant for which there is no contraindication at the time of inclusion in the study.

4. Patients in whom a pre-transplant blood sample can be drawn that is viable for the processing of an IMBG.

5. Patients who give their written informed consent to participate in the study.

Cross-sectional cohort:

1. Patients > 18 years of age.

2. Patients who have received a kidney transplant or re-transplant less than 3 years before inclusion in the study.

3. Patients in whom an indication biopsy is to be performed due to suspicion of rejection.

4. Patients in whom a blood sample can be drawn in a period of time less than 8 days before or after the Indication Biopsy that is viable for the processing of an IMBG.

5. Patients who give their written informed consent to participate in the study.

Exclusion Criteria (for both cohorts):

1. Patient with a double transplant (kidney + other organ).

2. Contraindication for performing a renal graft biopsy.

3. Active autoimmune diseases in the 12 months prior to the study visit (with systemic inflammatory exacerbation in the year prior to study inclusion, despite immunosuppressive therapy).

4. Very elderly cadaver donor transplant (>80 years of age).

5. Donors in asystole II.

6. Recurrent primary kidney disease in the case of primary focal and segmental hyalinosis or hemolytic-uremic syndrome.

7. Active HIV, HBV or HCV infection or other severe infections (to prevent risks in the processing of samples in conventional laboratories).

8. Concomitant medical conditions that may affect the patient's participation in the study.

Related Conditions & MeSH terms

• Kidney Transplant Failure and Rejection

Intervention

Diagnostic Test:
• Immunobiogram
This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.

Locations

Country	Name	City	State
Brazil	Hospital Do Rim	Brasil
France	University Hospital Grenoble	Grenoble
Germany	Charité Universitätsmedizin Berlin	Berlin
Germany	Universitätsklinikum Heidelberg	Heidelberg
Spain	Fundació Puigvert	Barcelona
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Universitario 12 Octubre	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Puerta de Hierro	Madrid
Spain	Hospital Universitario Puerta del Mar	Málaga
Spain	Hospital Universitario Marqués de Valdecilla	Santander
Spain	Hospital Universitario Dr. Peset	Valencia
Sweden	Uppsala University Hospital	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Biohope Scientific Solutions for Human Health, S.L.

Countries where clinical trial is conducted

Brazil,  France,  Germany,  Spain,  Sweden, 

References & Publications (3)

Pascual J, Crespo M, Portoles J, Jimenez C, Ortega-Carrion A, Diez T, Portero I. The IMBG Test for Evaluating the Pharmacodynamic Response to Immunosuppressive Therapy in Kidney Transplant Patients: Current Evidence and Future Applications. Int J Mol Sci. 2023 Mar 8;24(6):5201. doi: 10.3390/ijms24065201. — View Citation

Pascual J, Jimenez C, Krajewska M, Seron D, Kotton CN, Portoles J, Witzke O, Sorensen SS, Andres A, Crespo M, Paz-Artal E, Diez T, Ortega A, Portero I. The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients. Transpl Immunol. 2022 Dec;75:101711. doi: 10.1016/j.trim.2022.101711. Epub 2022 Sep 9. — View Citation

Portoles JM, Jimenez C, Janeiro D, Lopez-Oliva MO, Ortega-Carrion A, Blanquez D, Arribas L, Gomez C, Diez T, Pascual J, Portero I. The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy. Front Immunol. 2021 Jan 25;11:618202. doi: 10.3389/fimmu.2020.618202. eCollection 2020. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with BPAR in biopsies (following BANFF 2019 criteria) who present Low Sensitivity to the prescribed Immunosupressive drugs in IMBG	Proportion of patients with BPAR who present Low Sensitivity to the prescribed Immunosupressive drugs in IMBG Longitudinal cross-sectional cohorts 1 year- Protocol Biopsies and Indication Biopsies, BPAR following BANFF 2019 criteria.	12 months in the prospective follow-up cohort.
Secondary	Proportion of patients with therapeutical failure due to rejection who present low sensitivity to the prescribed immunosuppressive drugs in IMBG	Proportion of patients with therapeutical failure due to rejection who present low sensitivity to the prescribed immunosuppressive drugs in IMBG (Therapeutical failure is defined as the incidence of graft loss and/or BPAR and/or dnDSA)	12 months in the prospective follow-up cohort.
Secondary	Proportion of patients with with therapeutical failure due adverse effects attributable to immunosuppression who present high sensitivity /or low sensitivity and high doses to the prescribed immunosuppressive drugs in IMBG	Proportion of patients with with therapeutical failure due adverse effects attributable to immunosuppression who present high sensitivity /or low sensitivity and high doses to the prescribed immunosuppressive drugs in IMBG Therapeutical failure is defined as the incidence of opportunistic infection by Cytomegalovirus (CMV) (symptomatic or not) and/or BK polyomavirus (BKV) and/or 3 or more hospitalizations due to infections during the patient's follow-up).	12 months in the prospective follow-up cohort.
Secondary	Correlation between IMBG values and other lymphocyte activation markers	Correlation between IMBG values and other lymphocyte activation markers (CD69, CD25, IL-2, IFN-gamma) for each immunosuppressive drug tested with IMBG over time	In the prospective cohort at 3, 6, 9, and 12 months
Secondary	Distribution of pre-transplant IMBG values and post-transplant at 3, 6, 9, and 12 months	Distribution of pre-transplant IMBG values and post-transplant at 3, 6, 9, and 12 months	In the prospective cohort at 3, 6 , 9 and 12 months
Secondary	Adherence to treatment measured with Morisky Green Scale (MMAS).	Adherence to treatment measured with Morisky Green Scale (MMAS, score 0 (worst adherence) - 4 (best adherence), at 6 months and at one year.	at 6 and at 12 months
Secondary	Quality of Life perceived by the patient, measured with EQ-5D-5L questionnaire.	Quality of Life perceived by the patient, measured with European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire (score 0 (worst health) - 100 (best health) at baseline and at one year.	baseline and at 12 months

External Links

•   Biohope Scientific Solutions for Human Health, S.L.